Victoria Johnson

Infusion reaction rates and serum level lowering were similar between 120-minute and 60-minute infusion cohorts in the phase 4 AGILE study.

Tesser discussed the background of the phase 3 RESET-RA trial and efficacy findings.

Findings from PsABIOnd can help reassure clinicians of similar efficacy between treatment choices.

Arnold discussed his research in analyzing and improving current classifications of ANA-RMDs and how it could help improve research in the field.

Emapalumab may improve outcomes in patients with MAS whose disease didn't respond to steroid therapy and mitigate the need for more toxic therapies.

The findings are especially important as differences in disease characteristics and outcomes between male and female patients become more clear.

LEVI-04 (Levicept) , a first-in-class neurotrophin-3 (NT3) inhibitor, was well-tolerated and significantly and meaningfully improved pain, function, and other outcomes in people with osteoarthritis (OA).

Key Takeaways Anifrolumab significantly reduces organ damage risk in SLE patients compared to standard care, as shown in the LASER study.

Stone discussed the phase 3 MITIGATE study, other potential treatment strategies, and top research priorities moving forward for IgG4.

The investigators found that PRX-115 exposure increased in a dose–dependent manner with maximal concentrations observed, in general, immediately post-infusion, and PRX-115 remaining detectable in plasma for up to 12 weeks in cohorts 6, 7 and 8. A single dose of PRX-115 rapidly reduced plasma urate levels at all dose levels. At the highest dose levels, mean plasma urate levels remained below 6.0 mg/dL for up to 12 weeks.